
Agreement - April 21, 2017
Scandinavian Biopharma in agreement with Flynn Pharma
Scandinavian Biopharma has entered into an agreement with Flynn Pharma for the viper antivenom ViperaTAb. Under the agreement, Scandinavian Biopharma will have exclusive rights to service and make ViperaTAb available for emergency use in the Nordics, Baltic States and Germany. “We are very pleased to strengthen our portfolio with an important antivenom for Northern Europe” […]